Opinions
Cameron Hurst
Teva Pharmaceutical
TEVA-N
DON'T BUY
Nov 12, 2018
It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
$23.690
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology
pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology
pharmaceutical
DON'T BUY